Missed opportunities for hepatitis c testing in opioid treatment programs

J.A. Frimpong

American Journal of Public Health, 2013, vol. 103, issue 6, 1028-1030

Abstract: HCV has surpassed HIV as a cause of death in the United States and is particularly prevalent among injection drug users. I examined the availability of on-site HCV testing in a nationally representative sample of opioid treatment programs. Nearly 68% of these programs had the staff required for HCV testing, but only 34% offered on-site testing. Availability of on-site testing increased only slightly with the proportion of injection drug users among clients. The limited HCV testing services in opioid treatment programs is a key challenge to reducing HCV in the US population.

Keywords: narcotic analgesic agent, article; blood examination; drug dependence treatment; health care delivery; health care survey; hepatitis C; human; manpower; standard; statistics; substance abuse; United States, Analgesics, Opioid; Health Care Surveys; Health Services Accessibility; Hematologic Tests; Hepatitis C; Humans; Substance Abuse Treatment Centers; Substance Abuse, Intravenous; United States (search for similar items in EconPapers)
Date: 2013
References: Add references at CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.2105/AJPH.2012.301129

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:aph:ajpbhl:10.2105/ajph.2012.301129_4

DOI: 10.2105/AJPH.2012.301129

Access Statistics for this article

American Journal of Public Health is currently edited by Alfredo Morabia

More articles in American Journal of Public Health from American Public Health Association
Bibliographic data for series maintained by Christopher F Baum ().